ImageneBio (IMA) FCF Margin (2020 - 2025)

ImageneBio (IMA) posted FCF Margin of 903.75% for Q1 2025, down 344.03% sequentially from 370.34% in Q3 2024.

ImageneBio (IMA) FCF Margin (2020 - 2025) Analysis & Trends

ImageneBio has reported FCF Margin for 6 years, with the latest figure at 903.75% in Q1 2025.

Quarterly FCF Margin changed N/A year-over-year to 903.75% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 568.52% (changed N/A YoY) and the FY2023 annual result came in at 875.08%, down 39140.0% from the prior year.
FCF Margin eased to 903.75% in Q1 2025 per IMA's latest filing, from 370.34% in the prior quarter.
Over five years, FCF Margin peaked at 370.34% in Q3 2024 and troughed at 5330.1% in Q2 2022.
A 5-year average of 1055.33% and a median of 466.74% in 2021 frame the typical range for FCF Margin.
The sharpest annual moves came in 2021 and 2022: FCF Margin jumped 2025116 bps in 2021, then slumped 488178 bps in 2022.
Over 5 years, FCF Margin stood at 68.84% in 2021, then sank by 377 bps to 328.18% in 2022, then plunged by 921 bps to 3350.68% in 2023, then surged by 111 bps to 370.34% in 2024, then plunged by 344 bps to 903.75% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 903.75%, 370.34%, and 3350.68% for Q1 2025, Q3 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	138.53 Bn	130.68 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.34 Bn	78.35 Bn	3.93 Bn	13.35%
3	Argenx Se	64.67 Bn	59.48 Bn	1.37 Bn	-
4	Moderna	59.04 Bn	53.90 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.03 Bn	36.94 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.78 Bn	27.47 Bn	992.69 Mn	22.62%
7	BioNTech SE	27.81 Bn	9.42 Bn	668.28 Mn	41.07%
8	Insmed	27.21 Bn	26.05 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	26.99 Bn	26.15 Bn	-	70.82%
10	ImageneBio	49.67 Mn	-85.68 Mn	-	-

Download Data